Immunology and inflammation biotech company Bambusa (BBTX.US) IPO priced at $15-17 per share, aiming to raise $150 million.

Zhitong Finance APP has learned that Bambusa Therapeutics, a biotech company focused on immunology and inflammation, announced the terms of its initial public offering (IPO) on Monday. The company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 per share. Based on the midpoint of the proposed offering price range, Bambusa Therapeutics would have a fully diluted market capitalization of $837 million. The company plans to list on Nasdaq under the ticker symbol "BBTX." The IPO is expected to be priced during the week of October 26, 2026.